An artificial cardiac pacemaker, commonly referred to as simply a pacemaker, is an implanted medical device that generates electrical pulses delivered by electrodes to one or more of the chambers of the heart. Each pulse causes the targeted chamber(s) to contract and pump blood, thus regulating the function of the electrical conduction system of the heart.
A cochlear implant (CI) is a surgically implanted neuroprosthesis that provides a person who has moderate-to-profound sensorineural hearing loss with sound perception. With the help of therapy, cochlear implants may allow for improved speech understanding in both quiet and noisy environments. A CI bypasses acoustic hearing by direct electrical stimulation of the auditory nerve. Through everyday listening and auditory training, cochlear implants allow both children and adults to learn to interpret those signals as speech and sound.
Bone conduction is the conduction of sound to the inner ear primarily through the bones of the skull, allowing the hearer to perceive audio content even if the ear canal is blocked. Bone conduction transmission occurs constantly as sound waves vibrate bone, specifically the bones in the skull, although it is hard for the average individual to distinguish sound being conveyed through the bone as opposed to the sound being conveyed through the air via the ear canal. Intentional transmission of sound through bone can be used with individuals with normal hearing — as with bone-conduction headphones — or as a treatment option for certain types of hearing impairment. Bones are generally more effective at transmitting lower-frequency sounds compared to higher-frequency sounds.
Neuroprosthetics is a discipline related to neuroscience and biomedical engineering concerned with developing neural prostheses. They are sometimes contrasted with a brain–computer interface, which connects the brain to a computer rather than a device meant to replace missing biological functionality.
Sonova Holding AG is an internationally active Swiss group of companies headquartered in Stäfa that specializes in hearing care. The Sonova group operates through its core business brands Phonak, Unitron, Hansaton, Advanced Bionics, AudioNova and Sennheiser. It is one of the largest providers in the sector worldwide. The group and its brands hold 24% of the global hearing aid market in sales. As of 11 September 2022, Sonova was a component of the Swiss Market Index.
Graeme Milbourne Clark is an Australian Professor of Otolaryngology at the University of Melbourne. Worked in ENT surgery, electronics and speech science contributed towards the development of the multiple-channel cochlear implant. His invention was later marketed by Cochlear Limited.
The Greenwood function correlates the position of the hair cells in the inner ear to the frequencies that stimulate their corresponding auditory neurons. Empirically derived in 1961 by Donald D. Greenwood, the relationship has shown to be constant throughout mammalian species when scaled to the appropriate cochlear spiral lengths and audible frequency ranges. Moreover, the Greenwood function provides the mathematical basis for cochlear implant surgical electrode array placement within the cochlea.
The auditory brainstem response (ABR), also called brainstem evoked response audiometry (BERA) or brainstem auditory evoked potentials (BAEPs) or brainstem auditory evoked responses (BAERs) is an auditory evoked potential extracted from ongoing electrical activity in the brain and recorded via electrodes placed on the scalp. The measured recording is a series of six to seven vertex positive waves of which I through V are evaluated. These waves, labeled with Roman numerals in Jewett and Williston convention, occur in the first 10 milliseconds after onset of an auditory stimulus. The ABR is considered an exogenous response because it is dependent upon external factors.
Cochlear is a medical device company that designs, manufactures, and supplies the Nucleus cochlear implant, the Hybrid electro-acoustic implant and the Baha bone conduction implant.
Electric acoustic stimulation (EAS) is the use of a hearing aid and a cochlear implant technology together in the same ear. EAS is intended for people with high-frequency hearing loss, who can hear low-pitched sounds but not high-pitched ones. The hearing aid acoustically amplifies low-frequency sounds, while the cochlear implant electrically stimulates the middle- and high-frequency sounds. The inner ear then processes the acoustic and electric stimuli simultaneously, to give the patient the perception of sound.
An auditory brainstem implant (ABI) is a surgically implanted electronic device that provides a sense of sound to a person who is profoundly deaf, due to retrocochlear hearing impairment. In Europe, ABIs have been used in children and adults, and in patients with neurofibromatosis type II.
Geoffrey R. Ball (born 1964) is an American physiologist specializing in Biomechanics and the inventor of the VIBRANT SOUNDBRIDGE active middle ear implant – a medical device designed to treat his own hearing loss.
Neurostimulation is the purposeful modulation of the nervous system's activity using invasive or non-invasive means. Neurostimulation usually refers to the electromagnetic approaches to neuromodulation.
Erwin Hochmair is an Austrian electrical engineer whose research focuses in the fields of biomedical engineering and cochlear implant design. He has been a professor at the Institute of Experimental Physics, University of Innsbruck since 1986. He has authored and co-authored over 100 technical articles and holds about 50 patents. He is the co-founder and owner of the medical device company MED-EL.
Blake Shaw Wilson is an American research scientist best known for his role in developing signal processing strategies for the cochlear implant.
MED-EL is a global medical technology company specializing in hearing implants and devices. They develop and manufacture products including cochlear implants, middle ear implants and bone conduction systems.
The Bionics Institute is an Australian medical research institute focusing on medical device development. It is located in Melbourne, Australia.
Claude-Henri Chouard is a French surgeon. An otologist, he has been a full member of the Académie Nationale de Médecine since 1999. He was director of the AP-HP Laboratory of Auditory Prosthesis and director of the ENT Research Laboratory at Paris-Saint-Antoine University Hospital from 1967 to 2001. He was also head of the institution's ENT Department from 1978 to 1998. In 1982, he was elected a member of the International Collegium ORL-AS. He achieved worldwide recognition in the late 1970s thanks to the work completed by his Paris laboratory's multidisciplinary team on the multichannel cochlear implant. This implanted electronic hearing device was developed at Saint-Antoine and alleviates bilateral total deafness. When implanted early in young children, it can also help overcome the spoken language problems associated with deafness.
A chronic electrode implant is an electronic device implanted chronically into the brain or other electrically excitable tissue. It may record electrical impulses in the brain or may stimulate neurons with electrical impulses from an external source.
A totally implantable cochlear implant (TICI) is a new type of cochlear implant and is currently in development. Unlike a conventional cochlear implant, which has both an internal component and an external component, all the components of the TICI - including the microphone and battery - are implanted under the skin. This makes the TICI completely invisible from the outside.
